| scholarly article | Q13442814 |
| P50 | author | Todd Golub | Q7812388 |
| Rameen Beroukhim | Q88043871 | ||
| Adam J Bass | Q89556844 | ||
| Scott L Carter | Q90591598 | ||
| Andrey Sivachenko | Q104846634 | ||
| Robert Onofrio | Q114385358 | ||
| Shuji Ogino | Q18055035 | ||
| Eric Lander | Q970550 | ||
| Candace Guiducci | Q29840635 | ||
| Gad Getz | Q32646381 | ||
| Kristian Cibulskis | Q32646400 | ||
| Daniel Auclair | Q32646543 | ||
| Carrie Sougnez | Q28321195 | ||
| Tony E Godfrey | Q57487924 | ||
| Chip Stewart | Q61305792 | ||
| David G Beer | Q87761086 | ||
| Gordon Saksena | Q32646626 | ||
| Douglas Voet | Q32646808 | ||
| Stacey Gabriel | Q32649203 | ||
| Aaron McKenna | Q32650112 | ||
| Andrew C. Chang | Q37621533 | ||
| P2093 | author name string | Yu Imamura | |
| Alex H Ramos | |||
| Austin M Dulak | |||
| Erica Shefler | |||
| Michael S Lawrence | |||
| Lin Lin | |||
| Zhongren Zhou | |||
| James D Luketich | |||
| Arjun Pennathur | |||
| Santhoshi Bandla | |||
| Jules Lin | |||
| Petar Stojanov | |||
| Shouyong Peng | |||
| Steven E Schumacher | |||
| Cameron Fox | |||
| Rishindra Reddy | |||
| Kristin Thompson | |||
| Rodney Landrenau | |||
| P2860 | cites work | Profiling critical cancer gene mutations in clinical tumor samples | Q21562343 |
| Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins | Q22010788 | ||
| MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2 | Q24294814 | ||
| The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex | Q24316449 | ||
| Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma | Q24337664 | ||
| A landscape of driver mutations in melanoma | Q24603357 | ||
| COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer | Q24608391 | ||
| dbSNP: the NCBI database of genetic variation | Q24608672 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| GenePattern 2.0 | Q29614171 | ||
| The mutational landscape of head and neck squamous cell carcinoma | Q29614654 | ||
| GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists | Q29615019 | ||
| Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types | Q30423124 | ||
| A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries | Q30475515 | ||
| Melanoma genome sequencing reveals frequent PREX2 mutations | Q24610463 | ||
| miRBase: integrating microRNA annotation and deep-sequencing data | Q24615914 | ||
| Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer | Q24616117 | ||
| Ongoing and future developments at the Universal Protein Resource | Q24616298 | ||
| The genomic complexity of primary human prostate cancer | Q24617949 | ||
| ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion | Q24623558 | ||
| The UCSC Genome Browser database: update 2011 | Q24625811 | ||
| Initial genome sequencing and analysis of multiple myeloma | Q24629117 | ||
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| ORegAnno: an open-access community-driven resource for regulatory annotation | Q24648942 | ||
| Troyer syndrome protein spartin is mono-ubiquitinated and functions in EGF receptor trafficking | Q24681559 | ||
| Structural basis for mutual relief of the Rac guanine nucleotide exchange factor DOCK2 and its partner ELMO1 from their autoinhibited forms | Q27677251 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| A comparison of normalization methods for high density oligonucleotide array data based on variance and bias | Q27860710 | ||
| A method and server for predicting damaging missense mutations | Q27860835 | ||
| Comprehensive mapping of long-range interactions reveals folding principles of the human genome | Q28131819 | ||
| DOCK2 regulates Rac activation and cytoskeletal reorganization through interaction with ELMO1 | Q28182421 | ||
| Epidemiology and pathogenesis of esophageal cancer | Q28213313 | ||
| PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling | Q28253621 | ||
| Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators | Q28267500 | ||
| Comprehensive genomic characterization of squamous cell lung cancers | Q28274701 | ||
| Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines | Q28275084 | ||
| Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing | Q28275103 | ||
| Rac activation and inactivation control plasticity of tumor cell movement | Q28299776 | ||
| Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase | Q38330900 | ||
| ERBB2 kinase domain mutation in the lung squamous cell carcinoma | Q38513518 | ||
| Deregulated MYC expression induces dependence upon AMPK-related kinase 5. | Q39372073 | ||
| Mapping of homozygous deletions in verified esophageal adenocarcinoma cell lines and xenografts | Q39443467 | ||
| A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. | Q40549606 | ||
| Expression of seven main Rho family members in gastric carcinoma | Q40587668 | ||
| Human mutation rate associated with DNA replication timing | Q42085559 | ||
| A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). | Q43741084 | ||
| Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis | Q46839636 | ||
| Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma | Q47264599 | ||
| Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma. | Q51489470 | ||
| p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. | Q52858385 | ||
| Requirement for Rac1 in a K-ras induced lung cancer in the mouse. | Q53329326 | ||
| Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. | Q53606400 | ||
| Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. | Q54562020 | ||
| Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas | Q73117116 | ||
| Induction of chromosomal gene mutations in Escherichia coli by direct incorporation of oxidatively damaged nucleotides. New evaluation method for mutagenesis by damaged DNA precursors in vivo | Q74473358 | ||
| The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence | Q81290009 | ||
| Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus | Q82100207 | ||
| Gefitinib-sensitizing mutations in esophageal carcinoma | Q83364741 | ||
| Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes | Q83831946 | ||
| Discovering motifs in ranked lists of DNA sequences | Q33279806 | ||
| Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. | Q33282920 | ||
| p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele. | Q33304991 | ||
| Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine | Q33723645 | ||
| Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes | Q33762440 | ||
| ContEst: estimating cross-contamination of human samples in next-generation sequencing data | Q33976298 | ||
| Sequence analysis of mutations and translocations across breast cancer subtypes | Q34032470 | ||
| SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. | Q34140542 | ||
| Absolute quantification of somatic DNA alterations in human cancer | Q34271693 | ||
| Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples | Q34327021 | ||
| SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis | Q35216353 | ||
| ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers | Q35501591 | ||
| Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147. | Q35723623 | ||
| Rho GTPase expression in tumourigenesis: evidence for a significant link | Q36126283 | ||
| Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis | Q36205151 | ||
| Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma | Q36322862 | ||
| E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus | Q36620473 | ||
| Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion | Q37242449 | ||
| Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. | Q37250634 | ||
| Barrett esophagus: an update | Q37762151 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | whole genome sequencing | Q2068526 |
| adenocarcinoma | Q356033 | ||
| P304 | page(s) | 478-486 | |
| P577 | publication date | 2013-03-24 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity | |
| P478 | volume | 45 |
| Q48225751 | A Case-Control Study of the Genetic Variability in Reactive Oxygen Species-Metabolizing Enzymes in Melanoma Risk. |
| Q50446436 | A case of esophageal adenocarcinoma on long-term rapamycin monotherapy. |
| Q33751457 | A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy |
| Q30785429 | A framework for organizing cancer-related variations from existing databases, publications and NGS data using a High-performance Integrated Virtual Environment (HIVE) |
| Q36188784 | A functional module-based exploration between inflammation and cancer in esophagus |
| Q40698095 | A mutation profile for top-k patient search exploiting Gene-Ontology and orthogonal non-negative matrix factorization |
| Q64066834 | A novel 4-gene prognostic signature for hypermutated colorectal cancer |
| Q93035829 | A putative role for the aryl hydrocarbon receptor (AHR) gene in a patient with cyclical Cushing's disease |
| Q35218636 | A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage |
| Q38851714 | APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma |
| Q36399463 | ARID1A gene mutation in ovarian and endometrial cancers (Review). |
| Q54379905 | Absence of TERT promoter mutations in esophageal adenocarcinoma. |
| Q38166683 | Acetaldehyde and the genome: beyond nuclear DNA adducts and carcinogenesis |
| Q47162757 | Actionable mutations in canine hemangiosarcoma. |
| Q36544056 | Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma |
| Q47141406 | Adjuvant chemotherapy following trimodality therapy for esophageal carcinoma-Is the evidence sufficient? |
| Q26825957 | Advances in targeted therapies and new promising targets in esophageal cancer |
| Q50020845 | An evolutionary perspective on field cancerization. |
| Q47770082 | Analysis and Annotation of Whole-Genome or Whole-Exome Sequencing Derived Variants for Clinical Diagnosis |
| Q43590500 | Analysis and annotation of whole-genome or whole-exome sequencing-derived variants for clinical diagnosis |
| Q35005582 | Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry |
| Q43728022 | Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett's oesophagus |
| Q36029469 | Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus |
| Q33709588 | Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome |
| Q37236624 | Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. |
| Q36803517 | Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists |
| Q33959620 | Barrett's esophagus and cancer risk: how research advances can impact clinical practice |
| Q57807142 | Barrett's esophagus with high grade dysplasia is associated with non-esophageal cancer |
| Q30249783 | Base changes in tumour DNA have the power to reveal the causes and evolution of cancer |
| Q38575013 | Biomarkers and novel agents in esophago-gastric cancer: are we making progress? |
| Q38213141 | Biomarkers for dysplastic Barrett's: ready for prime time? |
| Q38278197 | CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q). |
| Q40859240 | CTCF/cohesin-binding sites are frequently mutated in cancer |
| Q35035236 | Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma |
| Q92988701 | Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein |
| Q54940982 | Casein kinase 1α: biological mechanisms and theranostic potential. |
| Q35510462 | Cell-of-origin chromatin organization shapes the mutational landscape of cancer |
| Q39090046 | Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. |
| Q33907067 | Chromatin-regulating proteins as targets for cancer therapy |
| Q26741429 | Circulating Tumor Cells in the Adenocarcinoma of the Esophagus |
| Q30276066 | Clearance of Dying Cells by Phagocytes: Mechanisms and Implications for Disease Pathogenesis. |
| Q42314661 | Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. |
| Q37059849 | Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients |
| Q42361543 | Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre. |
| Q39411073 | Clonality analysis of synchronous gastroesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing. |
| Q30768176 | Collection, integration and analysis of cancer genomic profiles: from data to insight |
| Q91473941 | Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma |
| Q52603962 | Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. |
| Q61799774 | Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples |
| Q35763725 | Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences |
| Q28244985 | Comprehensive molecular characterization of gastric adenocarcinoma |
| Q52684134 | Conference report: improving outcomes for gastrointestinal cancer in the UK. |
| Q57109201 | Conjugated Bile Acids Promote Invasive Growth of Esophageal Adenocarcinoma Cells and Cancer Stem Cell Expansion via Sphingosine 1-Phosphate Receptor 2-Mediated Yes-Associated Protein Activation |
| Q36334576 | Construction and analysis of three networks of genes and microRNAs in adenocarcinoma |
| Q58298598 | Coping with esophageal cancer approaches worldwide |
| Q36062064 | Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma |
| Q90702159 | Current advances of targeting HGF/c-Met pathway in gastric cancer |
| Q36996171 | DOCK2 confers immunity and intestinal colonization resistance to Citrobacter rodentium infection |
| Q37675217 | DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells |
| Q31120836 | Data on affected cancer-related genes in pediatric t(12;21)-positive acute lymphoblastic leukemia patients harboring unbalanced der(6)t(X;6) translocations |
| Q35632953 | Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma |
| Q64375047 | Dedicator of cytokinesis 2 silencing therapy inhibits neointima formation and improves blood flow in rat vein grafts |
| Q36413660 | Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer |
| Q38885266 | Deregulation of the FOXM1 target gene network and its coregulatory partners in oesophageal adenocarcinoma |
| Q48138303 | Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. |
| Q48095123 | Diagnostic marker signature for esophageal cancer from transcriptome analysis. |
| Q36768782 | Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy |
| Q30459320 | Disease mutant analysis identifies a new function of DAXX in telomerase regulation and telomere maintenance |
| Q38669769 | Disseminated tumour cells with highly aberrant genomes are linked to poor prognosis in operable oesophageal adenocarcinoma |
| Q57790170 | Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns |
| Q35774475 | Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism |
| Q38542060 | Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma |
| Q52671777 | Dock2 in the development of inflammation and cancer. |
| Q37191910 | Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus |
| Q39340502 | EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? |
| Q89556847 | Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model |
| Q36575301 | Early onset esophageal adenocarcinoma: a distinct molecular entity? |
| Q42332720 | Editorial on role of p53 in esophageal cancer from a meta-analysis of 16 studies by Fisher et al. |
| Q37438597 | Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. |
| Q26751209 | Emerging therapeutic targets in esophageal adenocarcinoma |
| Q36172082 | Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma |
| Q36132761 | Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma |
| Q42131289 | Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution |
| Q38734003 | Esophageal Cancer: New Insights into a Heterogenous Disease |
| Q92761225 | Esophageal cancer research today and tomorrow: Lessons from algae and other perspectives |
| Q28077495 | Etiology and Prevention of Esophageal Cancer |
| Q35792782 | Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus |
| Q28083964 | Evidence of cancer-promoting roles for AMPK and related kinases |
| Q50346766 | Evolution of Barrett's esophagus through space and time at single-crypt and whole-biopsy levels. |
| Q36968814 | Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus |
| Q35077715 | Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer |
| Q41642267 | Expanding the spectrum of ALK-rearranged renal cell carcinomas in children: Identification of a novel HOOK1-ALK fusion transcript |
| Q38530342 | Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. |
| Q41204382 | Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. |
| Q91800352 | Extracellular Matrix Degradation Products Downregulate Neoplastic Esophageal Cell Phenotype |
| Q38897134 | FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study |
| Q36242129 | Family history of esophageal cancer increases the risk of esophageal squamous cell carcinoma |
| Q90325570 | Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation |
| Q37190164 | Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma |
| Q35613258 | Frequency and distribution of Notch mutations in tumor cell lines |
| Q35073507 | From genomics to diagnostics of esophageal adenocarcinoma |
| Q91776817 | GEAMP, a novel gastroesophageal junction carcinoma cell line derived from a malignant pleural effusion |
| Q92412039 | Gastric squamous-columnar junction contains a large pool of cancer-prone immature osteopontin responsive Lgr5-CD44+ cells |
| Q36283677 | Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair. |
| Q88123698 | Gefitinib for oesophageal cancer: a cog in need of a wheel? |
| Q26786469 | Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis |
| Q36109030 | Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma |
| Q92563348 | Genetic aberrations in iPSCs are introduced by a transient G1/S cell cycle checkpoint deficiency |
| Q35666522 | Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma |
| Q49873966 | Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues |
| Q34434773 | Genetic landscape of esophageal squamous cell carcinoma |
| Q37176105 | Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma |
| Q34449957 | Genetics of familial melanoma: 20 years after CDKN2A. |
| Q28271584 | Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes |
| Q51121654 | Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis. |
| Q64091919 | Genome-wide tracts of homozygosity and exome analyses reveal repetitive elements with Barrets esophagus/esophageal adenocarcinoma risk |
| Q36917828 | Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer |
| Q36454484 | Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma |
| Q35266369 | Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma |
| Q40427700 | Genomic analysis of HPV-positive versus HPV-negative oesophageal adenocarcinoma identifies a differential mutational landscape |
| Q103804153 | Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction |
| Q38651767 | Genomic approaches to accelerate cancer interception |
| Q34445264 | Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. |
| Q36299617 | Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development |
| Q26768533 | Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing |
| Q41198823 | Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing |
| Q92454107 | Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma |
| Q39096557 | Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing |
| Q49283122 | Genomic landscape of colitis-associated cancer indicates the impact of chronic inflammation and its stratification by mutations in the Wnt signaling |
| Q37688154 | Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas |
| Q38940530 | Genomics of Esophageal Cancer and Biomarkers for Early Detection |
| Q33600507 | Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective |
| Q50037163 | Germline variant in MSX1 identified in a Dutch family with clustering of Barrett's esophagus and esophageal adenocarcinoma |
| Q38893221 | Global trends in esophageal cancer |
| Q55435916 | Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. |
| Q90481894 | Grainyhead-like 2 as a double-edged sword in development and cancer |
| Q38218298 | Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy |
| Q60915393 | HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma |
| Q39104065 | Helicobacter pylori-Mediated Genetic Instability and Gastric Carcinogenesis |
| Q35841658 | Hepatocyte-Specific Arid1a Deficiency Initiates Mouse Steatohepatitis and Hepatocellular Carcinoma. |
| Q57294534 | Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells |
| Q90116644 | HiLDA: a statistical approach to investigate differences in mutational signatures |
| Q49301622 | High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer. |
| Q38484630 | High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells |
| Q28242124 | High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families |
| Q36335903 | Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer |
| Q38268784 | How the environment shapes cancer genomes |
| Q28255066 | Hypermutation in human cancer genomes: footprints and mechanisms |
| Q38704019 | ISOWN: accurate somatic mutation identification in the absence of normal tissue controls |
| Q47134720 | Identification and validation of FGFR2 peptide for detection of early Barrett's neoplasia |
| Q64074752 | Identification of a primitive intestinal transcription factor network shared between esophageal adenocarcinoma and its precancerous precursor state |
| Q99583850 | Identification of critical radioresistance genes in esophageal squamous cell carcinoma by whole-exome sequencing |
| Q38599134 | Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas. |
| Q55002251 | Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer. |
| Q34412178 | Identification of genomic alterations in oesophageal squamous cell cancer |
| Q36725997 | Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma |
| Q92247572 | Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma |
| Q59357687 | Immune signatures correlate with L1 retrotransposition in gastrointestinal cancers |
| Q33769334 | Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis. |
| Q41447028 | Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer |
| Q38831897 | In silico dissection of miRNA targetome polymorphisms and their role in regulating miRNA-mediated gene expression in esophageal cancer. |
| Q28303563 | Inactivating CUX1 mutations promote tumorigenesis |
| Q91865172 | Ingested asbestos in filtered beer, in addition to occupational exposure, as a causative factor in oesophageal adenocarcinoma |
| Q38134486 | Inhibition of Hedgehog signaling in the gastrointestinal tract: targeting the cancer microenvironment. |
| Q64389367 | Inhibition of RAD54B suppresses proliferation and promotes apoptosis in hepatoma cells |
| Q38196631 | Insights into the biological functions of Dock family guanine nucleotide exchange factors |
| Q47950548 | Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma |
| Q38587601 | Integrated Transcriptomic-Proteomic Analysis Using a Proteogenomic Workflow Refines Rat Genome Annotation |
| Q36859396 | Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. |
| Q39041152 | Integrated genomic characterization of oesophageal carcinoma |
| Q37593285 | Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas |
| Q37595614 | Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers |
| Q34586242 | Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma |
| Q89303878 | Is Barrett's-Associated Esophageal Adenocarcinoma a Clonal Disease? |
| Q92915778 | Is phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway therapeutic target for esophageal adenocarcinoma |
| Q37534894 | Knockdown of ELMO3 Suppresses Growth, Invasion and Metastasis of Colorectal Cancer |
| Q36713548 | Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines |
| Q97905998 | Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma |
| Q92450415 | Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma |
| Q27853197 | Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer |
| Q57810109 | Maftools: efficient and comprehensive analysis of somatic variants in cancer |
| Q38613413 | Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer |
| Q33882085 | Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer |
| Q35687336 | Mobile element insertions are frequent in oesophageal adenocarcinomas and can mislead paired-end sequencing analysis |
| Q59353924 | Modeling Wnt signaling by CRISPR-Cas9 genome editing recapitulates neoplasia in human Barrett epithelial organoids |
| Q88687901 | Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus |
| Q55654316 | Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. |
| Q36335009 | Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples |
| Q36750684 | Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma |
| Q90665246 | Molecular epigenomic subtypes of Barrett neoplasia |
| Q28070583 | Molecular predictive markers in tumors of the gastrointestinal tract |
| Q39235977 | Molecular subtypes in cancers of the gastrointestinal tract |
| Q36853563 | Multiplex Preamplification of Serum DNA to Facilitate Reliable Detection of Extremely Rare Cancer Mutations in Circulating DNA by Digital PCR. |
| Q92482661 | Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma |
| Q38623890 | Mutation Clusters from Cancer Exome |
| Q52691469 | Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers. |
| Q36578527 | Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair |
| Q58756653 | Mutational signature distribution varies with DNA replication timing and strand asymmetry |
| Q38748208 | Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. |
| Q89720494 | Mutational signatures: experimental design and analytical framework |
| Q26850125 | Mutational signatures: the patterns of somatic mutations hidden in cancer genomes |
| Q36528097 | Mutational spectrum of Barrett's stem cells suggests paths to initiation of a precancerous lesion |
| Q33600399 | Mutations of Chromatin Structure Regulating Genes in Human Malignancies |
| Q51746842 | NSAID use and somatic exomic mutations in Barrett's esophagus. |
| Q28086781 | Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment |
| Q42034112 | Network-based stratification of tumor mutations |
| Q38160836 | New and emerging treatment options for biliary tract cancer |
| Q89638561 | Novel ESCC-related gene ZNF750 as potential Prognostic biomarker and inhibits Epithelial-Mesenchymal Transition through directly depressing SNAI1 promoter in ESCC |
| Q36189276 | Novel Lys63-linked ubiquitination of IKKβ induces STAT3 signaling |
| Q39171565 | Novel Targeted Therapies for Esophagogastric Cancer |
| Q30441193 | Novel insight into mutational landscape of head and neck squamous cell carcinoma |
| Q35351133 | Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer |
| Q48502077 | Oesophageal Stem Cells and Cancer |
| Q38816897 | Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? |
| Q88616304 | Oesophageal cancer |
| Q38599774 | Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma |
| Q55280819 | Optimal Collaborative Management of Patients With Esophagogastric Cancers. |
| Q33975855 | Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. |
| Q57900923 | Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics |
| Q38435302 | Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma. |
| Q36004465 | Paired exome analysis of Barrett's esophagus and adenocarcinoma |
| Q90129973 | Passenger Hotspot Mutations in Cancer |
| Q47154860 | Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma. |
| Q39453553 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies |
| Q52581750 | Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. |
| Q38943113 | Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma. |
| Q35042479 | Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus |
| Q64054064 | Portrait of a cancer: mutational signature analyses for cancer diagnostics |
| Q38824375 | Potentially Curable Cancers of the Esophagus and Stomach. |
| Q35243217 | Precision prevention of oesophageal adenocarcinoma |
| Q37499021 | Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer |
| Q35225642 | Prediction of long noncoding RNA functions with co-expression network in esophageal squamous cell carcinoma |
| Q35145369 | Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma |
| Q38677878 | Prevalence and Significance of HMGA2 Expression in Esophageal Adenocarcinoma. |
| Q34734133 | Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. |
| Q64235429 | Prognostic impact of family history of cancer in Southern Chinese patients with esophageal squamous cell cancer |
| Q35203134 | Protein domain-level landscape of cancer-type-specific somatic mutations |
| Q60309641 | Quantification of somatic mutation flow across individual cell division events by lineage sequencing |
| Q59912703 | Quantitative proteomic profiling of primary cancer-associated fibroblasts in oesophageal adenocarcinoma |
| Q35051834 | RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer |
| Q38752935 | RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas |
| Q38714000 | RNA sequencing of esophageal adenocarcinomas identifies novel fusion transcripts, including NPC1-MELK, arising from a complex chromosomal rearrangement. |
| Q37389361 | Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. |
| Q26769014 | Reactivation of telomerase in cancer |
| Q33589301 | Recent advances in preoperative management of esophageal adenocarcinoma |
| Q40211104 | Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma |
| Q37536791 | Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma |
| Q46268209 | Reduced mutation rate in exons due to differential mismatch repair |
| Q41472107 | Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis |
| Q37215328 | Research advances in esophageal diseases: bench to bedside |
| Q35067345 | Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas |
| Q33825098 | Ribosomal DNA copy number loss and sequence variation in cancer |
| Q98210339 | Risk factors for precancerous lesions of esophageal squamous cell carcinoma in high-risk areas of rural China: A population-based screening study |
| Q38839797 | Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. |
| Q34348631 | Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. |
| Q42284390 | Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways |
| Q42127711 | Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation. |
| Q38904246 | Runx3 in Immunity, Inflammation and Cancer |
| Q92675551 | STAG Mutations in Cancer |
| Q26998657 | SWI/SNF chromatin remodeling complexes and cancer |
| Q89285948 | Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective? |
| Q35085793 | SeqBench: integrated solution for the management and analysis of exome sequencing data. |
| Q27026253 | Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction |
| Q29547191 | Signatures of mutational processes in human cancer |
| Q36159205 | Simul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling |
| Q35218771 | Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival |
| Q34409666 | Strategies to improve outcomes in esophageal adenocarcinoma. |
| Q51048878 | Strategy for prevention of cancers of the esophagus. |
| Q43226865 | Structural Analysis of the Pin1-CPEB1 interaction and its potential role in CPEB1 degradation. |
| Q27929935 | Structural integrity of centromeric chromatin and faithful chromosome segregation requires Pat1 |
| Q51832891 | Studying Cancer Evolution in Barrett's Esophagus and Esophageal Adenocarcinoma. |
| Q54976655 | Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. |
| Q26852061 | Surgery in the era of the 'omics revolution |
| Q37059872 | Surrogate Markers: Lessons from the Next Gen? |
| Q28085367 | Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma |
| Q91623094 | Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer |
| Q36081375 | TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients |
| Q37256055 | TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism |
| Q35021377 | TET proteins and the control of cytosine demethylation in cancer |
| Q45314404 | TGFBR1 LBD Mutants in Cancer |
| Q50288851 | TGFBR2 does not recruit TGFBR1 LBD Mutants |
| Q34219975 | TGM2: a cell surface marker in esophageal adenocarcinomas. |
| Q46036182 | TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing. |
| Q35634450 | Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms |
| Q38634870 | Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival |
| Q49961144 | Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma |
| Q38856729 | Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges |
| Q38157714 | Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy |
| Q64993592 | Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. |
| Q37524048 | Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus |
| Q38132057 | The '-omics' revolution and oesophageal adenocarcinoma |
| Q34505489 | The Chromatin Regulator BRPF3 Preferentially Activates the HBO1 Acetyltransferase but Is Dispensable for Mouse Development and Survival |
| Q39440077 | The Evolving Genomic Landscape of Barrett's Esophagus and Esophageal Adenocarcinoma |
| Q60921528 | The Network of Cancer Genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens |
| Q60960098 | The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy |
| Q38969484 | The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. |
| Q41084526 | The Transcriptional Landscape of p53 Signalling Pathway |
| Q40374172 | The biological significance of methylome differences in human papilloma virus associated head and neck cancer |
| Q53087702 | The cancer genome: from structure to function. |
| Q34467243 | The chromatin regulator Brpf1 regulates embryo development and cell proliferation |
| Q37488137 | The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma |
| Q33910495 | The dynamic exome: acquired variants as individuals age. |
| Q38831655 | The emerging role of immunotherapy in gastric and esophageal adenocarcinoma |
| Q38195175 | The emerging roles of ARID1A in tumor suppression |
| Q39179722 | The enigmatic oncogene and tumor suppressor-like properties of RAD54B: Insights into genome instability and cancer |
| Q39183864 | The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring |
| Q36225715 | The genomic landscape of juvenile myelomonocytic leukemia |
| Q34389892 | The genomic landscape of oesophagogastric junctional adenocarcinoma |
| Q93014579 | The genomics of oxidative DNA damage, repair, and resulting mutagenesis |
| Q41992804 | The human TLR4 variant D299G mediates inflammation-associated cancer progression in the intestinal epithelium |
| Q91341661 | The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic |
| Q58617586 | The many lives of KATs - detectors, integrators and modulators of the cellular environment |
| Q36656549 | The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening |
| Q96639903 | The mutREAD method detects mutational signatures from low quantities of cancer DNA |
| Q38687715 | The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis |
| Q35818437 | The role of intracellular calcium for the development and treatment of neuroblastoma |
| Q58484627 | Therapeutic approaches to gastroesophageal junction adenocarcinomas |
| Q98944980 | Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor |
| Q35929463 | Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy |
| Q30239109 | Translating genomic profiling to gastrointestinal cancer treatment |
| Q58426138 | Tumors of the upper aerodigestive tract |
| Q94392976 | UEG Week 2015 Oral Presentations |
| Q38840433 | Understanding mutagenesis through delineation of mutational signatures in human cancer |
| Q38684349 | Update on Gastroesophageal Adenocarcinoma Targeted Therapies |
| Q36355920 | Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? |
| Q57797057 | WWOX, the FRA16D gene: a target of and a contributor to genomic instability |
| Q90710914 | Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy |
| Q37610120 | Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers |
| Q38307191 | Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. |
| Q58118126 | Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations |
| Q38748225 | Whole-genome sequencing of nine esophageal adenocarcinoma cell lines |
| Q36015250 | Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma |
| Q64240600 | p53 overexpression is a prognosticator of poor outcome in esophageal cancer |
| Q55317227 | siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth. |
Search more.